Key facts
- Solve Chemistry’s last known valuation is $3.8M (Jul 2024).
- It has raised $6.4M; the latest was Seed Round ($5.4M) in Jan 2026.
- Notable investors include XTX Ventures, BASF, Creator Fund, Debora Fang, Endgame Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Solve Chemistry
- ·The full record, as it builds
Funding rounds
No funding rounds for Solve Chemistry are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Solve Chemistry
Developer of an automated chemical process development platform designed to accelerate organic synthesis and optimize reaction conditions. The company's platform offers throughput experimentation for rapid and precise chemical reaction data collection, advanced machine learning models to analyze complex reaction patterns and predict outcomes, and micro-kinetic analysis to generate scale-independent kinetic models that guide process development and scale-up with accuracy and confidence, enabling pharmaceutical and agrochemical companies to make quick, data-driven decisions and scale processes efficiently with reduced risk and resource consumption.
- Sector
- Business Products and Services (B2B)
- HQ
- London, United Kingdom
- Founded
- 2024
- Employees
- 17
- Website
- solvechemistry.com/
- Ownership
- Privately Held (backing)
Solve Chemistry doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Solve Chemistry shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Solve Chemistry in its N-PORT filings yet. We sweep new filings monthly.